DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model

Nielson T. Baxter, Charles C. Koumpouras, Mary A.M. Rogers, Mack T. Ruffin, Patrick D. Schloss

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background: There is a significant demand for colorectal cancer (CRC) screening methods that are noninvasive, inexpensive, and capable of accurately detecting early stage tumors. It has been shown that models based on the gut microbiota can complement the fecal occult blood test and fecal immunochemical test (FIT). However, a barrier to microbiota-based screening is the need to collect and store a patient's stool sample. Results: Using stool samples collected from 404 patients, we tested whether the residual buffer containing resuspended feces in FIT cartridges could be used in place of intact stool samples. We found that the bacterial DNA isolated from FIT cartridges largely recapitulated the community structure and membership of patients' stool microbiota and that the abundance of bacteria associated with CRC were conserved. We also found that models for detecting CRC that were generated using bacterial abundances from FIT cartridges were equally predictive as models generated using bacterial abundances from stool. Conclusions: These findings demonstrate the potential for using residual buffer from FIT cartridges in place of stool for microbiota-based screening for CRC. This may reduce the need to collect and process separate stool samples and may facilitate combining FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges could constitute a novel data source for studying the role of the microbiome in cancer and other diseases.

Original languageEnglish (US)
Article number59
JournalMicrobiome
Volume4
DOIs
StatePublished - Jan 1 2016

Fingerprint

Microbiota
Colorectal Neoplasms
DNA
Buffers
Bacterial DNA
Occult Blood
Information Storage and Retrieval
Hematologic Tests
Early Detection of Cancer
Feces
Neoplasms
Biomarkers
Bacteria

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)

Cite this

Baxter, Nielson T. ; Koumpouras, Charles C. ; Rogers, Mary A.M. ; Ruffin, Mack T. ; Schloss, Patrick D. / DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. In: Microbiome. 2016 ; Vol. 4.
@article{bb898a84fd07497487efa9401e1e2821,
title = "DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model",
abstract = "Background: There is a significant demand for colorectal cancer (CRC) screening methods that are noninvasive, inexpensive, and capable of accurately detecting early stage tumors. It has been shown that models based on the gut microbiota can complement the fecal occult blood test and fecal immunochemical test (FIT). However, a barrier to microbiota-based screening is the need to collect and store a patient's stool sample. Results: Using stool samples collected from 404 patients, we tested whether the residual buffer containing resuspended feces in FIT cartridges could be used in place of intact stool samples. We found that the bacterial DNA isolated from FIT cartridges largely recapitulated the community structure and membership of patients' stool microbiota and that the abundance of bacteria associated with CRC were conserved. We also found that models for detecting CRC that were generated using bacterial abundances from FIT cartridges were equally predictive as models generated using bacterial abundances from stool. Conclusions: These findings demonstrate the potential for using residual buffer from FIT cartridges in place of stool for microbiota-based screening for CRC. This may reduce the need to collect and process separate stool samples and may facilitate combining FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges could constitute a novel data source for studying the role of the microbiome in cancer and other diseases.",
author = "Baxter, {Nielson T.} and Koumpouras, {Charles C.} and Rogers, {Mary A.M.} and Ruffin, {Mack T.} and Schloss, {Patrick D.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1186/s40168-016-0205-y",
language = "English (US)",
volume = "4",
journal = "Microbiome",
issn = "2049-2618",
publisher = "BioMed Central",

}

DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. / Baxter, Nielson T.; Koumpouras, Charles C.; Rogers, Mary A.M.; Ruffin, Mack T.; Schloss, Patrick D.

In: Microbiome, Vol. 4, 59, 01.01.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model

AU - Baxter, Nielson T.

AU - Koumpouras, Charles C.

AU - Rogers, Mary A.M.

AU - Ruffin, Mack T.

AU - Schloss, Patrick D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: There is a significant demand for colorectal cancer (CRC) screening methods that are noninvasive, inexpensive, and capable of accurately detecting early stage tumors. It has been shown that models based on the gut microbiota can complement the fecal occult blood test and fecal immunochemical test (FIT). However, a barrier to microbiota-based screening is the need to collect and store a patient's stool sample. Results: Using stool samples collected from 404 patients, we tested whether the residual buffer containing resuspended feces in FIT cartridges could be used in place of intact stool samples. We found that the bacterial DNA isolated from FIT cartridges largely recapitulated the community structure and membership of patients' stool microbiota and that the abundance of bacteria associated with CRC were conserved. We also found that models for detecting CRC that were generated using bacterial abundances from FIT cartridges were equally predictive as models generated using bacterial abundances from stool. Conclusions: These findings demonstrate the potential for using residual buffer from FIT cartridges in place of stool for microbiota-based screening for CRC. This may reduce the need to collect and process separate stool samples and may facilitate combining FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges could constitute a novel data source for studying the role of the microbiome in cancer and other diseases.

AB - Background: There is a significant demand for colorectal cancer (CRC) screening methods that are noninvasive, inexpensive, and capable of accurately detecting early stage tumors. It has been shown that models based on the gut microbiota can complement the fecal occult blood test and fecal immunochemical test (FIT). However, a barrier to microbiota-based screening is the need to collect and store a patient's stool sample. Results: Using stool samples collected from 404 patients, we tested whether the residual buffer containing resuspended feces in FIT cartridges could be used in place of intact stool samples. We found that the bacterial DNA isolated from FIT cartridges largely recapitulated the community structure and membership of patients' stool microbiota and that the abundance of bacteria associated with CRC were conserved. We also found that models for detecting CRC that were generated using bacterial abundances from FIT cartridges were equally predictive as models generated using bacterial abundances from stool. Conclusions: These findings demonstrate the potential for using residual buffer from FIT cartridges in place of stool for microbiota-based screening for CRC. This may reduce the need to collect and process separate stool samples and may facilitate combining FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges could constitute a novel data source for studying the role of the microbiome in cancer and other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84995801941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995801941&partnerID=8YFLogxK

U2 - 10.1186/s40168-016-0205-y

DO - 10.1186/s40168-016-0205-y

M3 - Review article

C2 - 27842559

AN - SCOPUS:84995801941

VL - 4

JO - Microbiome

JF - Microbiome

SN - 2049-2618

M1 - 59

ER -